INHIBITION OF HUMAN α5β1 INTEGRIN

DOP2026000072AUndetermined Publication Date: 2026-06-15MORPHIC THERAPEUTIC INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DO · DO
Patent Type
Applications
Current Assignee / Owner
MORPHIC THERAPEUTIC INC
Filing Date
2026-03-16
Publication Date
2026-06-15
Patent Text Reader

Abstract

Compounds of Formula (I) are described that can be used in the treatment or prevention of a disease or condition responsive to the inhibition of human α5β1 integrin by administering a compound of Formula (I) to a patient in need. Many diseases and conditions can be treated by administering a compound of Formula (I).
Need to check novelty before this filing date? Find Prior Art